Emerging Diagnostic Tools and Therapeutic Approaches for Liver Cirrhosis Management.

IF 2.8 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Subhrojyoti Mukherjee, Manish Kumar, Somnath Das, Sheeba Shafi, Shruti Srivastava, Manoj Kumar Mishra, Arun Kumar Singh, Ravi Raj Pal
{"title":"Emerging Diagnostic Tools and Therapeutic Approaches for Liver Cirrhosis Management.","authors":"Subhrojyoti Mukherjee, Manish Kumar, Somnath Das, Sheeba Shafi, Shruti Srivastava, Manoj Kumar Mishra, Arun Kumar Singh, Ravi Raj Pal","doi":"10.2174/0113816128444314260409071748","DOIUrl":null,"url":null,"abstract":"<p><p>Liver cirrhosis, a chronic liver disease identified by the formation of regenerative nodules along with fibrous bands, poses significant challenges in diagnosis and treatment. In the world, the most common factors of cirrhosis are Hepatitis C Virus (HCV), alcoholic liver disease, and Non-Alcoholic Steatohepatitis (NASH). The disease develops from a presymptomatic phase to a symptomatic phase, which often results in hospitalization, poor quality of life, and high mortality. The treatment of liver cirrhosis is centred on the treatment of the causes and complications, and liver transplantation is required in some cases. This mini-review explores innovative strategies in liver cirrhosis detection and intervention, highlighting recent advancements and future directions. Current diagnostic methods include physical examination and serologic tests detecting secondary indicators of liver dysfunction and fibrosis. Diagnostic tools encompass established biomarkers such as serum albumin, prothrombin time, bile acid levels, and platelet count, as well as AI-assisted diagnostic tools that use digital imaging and pathology data. Novel therapeutic approaches like antifibrotic agents, targeted therapies for specific etiologies, endoscopic interventions, and innovative stem cell-based therapies, particularly mesenchymal stem cells, offer promising approaches for liver regeneration and fibrosis reduction through their multidirectional differentiation potential and secretion of cytokines, growth factors, and matrix metalloproteinases. However, additional studies are required to enhance the effectiveness of these interventions. Future directions emphasize primary prevention, early fibrosis screening using non-invasive testing, and active targeting of fibrogenesis pathways. More clinical studies are essential to treat cirrhosis and improve patient outcomes.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128444314260409071748","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Liver cirrhosis, a chronic liver disease identified by the formation of regenerative nodules along with fibrous bands, poses significant challenges in diagnosis and treatment. In the world, the most common factors of cirrhosis are Hepatitis C Virus (HCV), alcoholic liver disease, and Non-Alcoholic Steatohepatitis (NASH). The disease develops from a presymptomatic phase to a symptomatic phase, which often results in hospitalization, poor quality of life, and high mortality. The treatment of liver cirrhosis is centred on the treatment of the causes and complications, and liver transplantation is required in some cases. This mini-review explores innovative strategies in liver cirrhosis detection and intervention, highlighting recent advancements and future directions. Current diagnostic methods include physical examination and serologic tests detecting secondary indicators of liver dysfunction and fibrosis. Diagnostic tools encompass established biomarkers such as serum albumin, prothrombin time, bile acid levels, and platelet count, as well as AI-assisted diagnostic tools that use digital imaging and pathology data. Novel therapeutic approaches like antifibrotic agents, targeted therapies for specific etiologies, endoscopic interventions, and innovative stem cell-based therapies, particularly mesenchymal stem cells, offer promising approaches for liver regeneration and fibrosis reduction through their multidirectional differentiation potential and secretion of cytokines, growth factors, and matrix metalloproteinases. However, additional studies are required to enhance the effectiveness of these interventions. Future directions emphasize primary prevention, early fibrosis screening using non-invasive testing, and active targeting of fibrogenesis pathways. More clinical studies are essential to treat cirrhosis and improve patient outcomes.

肝硬化管理的新兴诊断工具和治疗方法。
肝硬化是一种慢性肝病,其特征是再生结节和纤维带的形成,在诊断和治疗方面提出了重大挑战。在世界范围内,肝硬化最常见的因素是丙型肝炎病毒(HCV)、酒精性肝病和非酒精性脂肪性肝炎(NASH)。该病从症状前阶段发展到症状期,通常导致住院治疗,生活质量差,死亡率高。肝硬化的治疗主要集中在病因和并发症的治疗上,在某些情况下需要肝移植。这篇小型综述探讨了肝硬化检测和干预的创新策略,突出了最近的进展和未来的方向。目前的诊断方法包括体格检查和血清学检查,以检测肝功能障碍和纤维化的次要指标。诊断工具包括已建立的生物标志物,如血清白蛋白、凝血酶原时间、胆汁酸水平和血小板计数,以及使用数字成像和病理数据的人工智能辅助诊断工具。新的治疗方法,如抗纤维化药物、针对特定病因的靶向治疗、内窥镜干预和创新的干细胞治疗,特别是间充质干细胞,通过其多向分化潜力和细胞因子、生长因子和基质金属蛋白酶的分泌,为肝脏再生和纤维化减少提供了有希望的方法。然而,需要进一步的研究来提高这些干预措施的有效性。未来的方向强调初级预防,使用无创检测进行早期纤维化筛查,以及纤维形成途径的主动靶向。更多的临床研究对于治疗肝硬化和改善患者预后至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书